VX 993
Alternative Names: VX-993Latest Information Update: 11 Jun 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 11 Jun 2024 CTP Push700373213: Updated KDM, and trial initiation HE added
- 09 May 2024 Phase-I clinical trials in Pain (In volunteers) in USA (IV) (NCT06394167)
- 07 May 2024 Vertex Pharmaceuticals plans a phase I trial for Pain (In Volunteers) (IV) in May 2024 (NCT06394167)